Corporate Governance - The company has established a fair and transparent performance evaluation and incentive mechanism for senior management [10]. - The company has maintained independent ownership of its assets, ensuring no significant ownership disputes exist [12]. - The company has a robust corporate governance structure, with clear separation of powers among the board, supervisory board, and management [13]. - The company has improved its corporate governance structure in compliance with relevant laws and regulations, ensuring clear responsibilities among shareholders, the board of directors, and management [30]. - The board of directors attended 7 meetings, with all members present at least once, indicating strong engagement in governance [41]. - The company has maintained a high level of attendance at shareholder meetings, with all directors participating in at least 3 meetings [41]. - The company has not reported any instances of directors failing to attend meetings consecutively, reflecting stable governance practices [41]. - The company has established a complete governance structure to ensure the protection of shareholder and creditor rights [100]. - The company has committed to maintaining an independent organizational structure and management system [113]. - The company has established independent financial accounting systems and management practices to ensure operational integrity [141]. Shareholder Relations - The company has actively monitored shareholder interests and ensuring equal rights for all shareholders [9]. - The company is committed to timely and efficient decision-making processes to protect the rights of all shareholders [28]. - The company has engaged in multiple investor communications throughout 2022, discussing operational conditions and new drug developments [27]. - The company has not provided any materials to investors during its communications, focusing solely on operational updates [27]. - The company has confirmed that all commitments made during the acquisition process have been fulfilled [116]. - The company has committed to reducing and standardizing related party transactions, ensuring fair pricing based on market standards [107]. - The company has guaranteed the independence of its financial decisions and operations, ensuring no interference from controlling shareholders [113]. - The company has confirmed that there are no competing businesses controlled by the major shareholder, ensuring no conflicts with the company's operations [138]. Financial Performance - The company reported a positive net profit for the reporting period, with the parent company's distributable profits being positive but no cash dividend distribution plan proposed [48]. - The company reported a total registered capital of 100 million yuan for its subsidiary, Harbin Saint Tai Biological Pharmaceutical Co., Ltd., with total assets of approximately 2.6 billion yuan [72]. - The subsidiary generated operating income of approximately 705 million yuan and a net profit of about 752 million yuan during the reporting period [72]. - The company has not reported any non-operational fund occupation by major shareholders or related parties during the reporting period [158]. - The company has not undergone any bankruptcy restructuring during the reporting period, reflecting financial stability [149]. Environmental Compliance - The average COD discharge concentration was 12.73 mg/L, and ammonia nitrogen discharge concentration was 0.148 mg/L, complying with relevant pollution discharge standards [60]. - The company has a total COD discharge of 3.28 tons and ammonia nitrogen discharge of 0.038 tons, with no exceedance of discharge limits reported [60]. - The company has a total of 1 wastewater discharge outlet located at the sewage station, ensuring compliance with environmental regulations [60]. - The company has a pollution discharge permit valid until November 20, 2027, ensuring adherence to environmental protection laws [59]. - The company has implemented advanced pollution control technologies, achieving a desulfurization efficiency of 90% and a dust removal efficiency of 99.5% [96]. - The company has invested CNY 1,929,041.50 in environmental governance and protection during the reporting period [99]. - The company has implemented emergency response plans for sudden environmental events [122]. - The company emphasizes internal management and compliance to strengthen its governance structure and risk control [78]. Research and Development - The company is committed to enhancing its research and development capabilities to ensure the successful completion of product development and market launch goals [57]. - The company plans to accelerate key R&D projects, including the development of new drugs, to enhance product technology and market competitiveness [78]. - The company has identified risks associated with new product development, emphasizing the need for careful project selection and effective risk management mechanisms [57]. Employee Management - The total number of employees at the end of the reporting period was 1,696, with 709 in the parent company and 987 in major subsidiaries [63]. - The employee composition included 880 production personnel, 314 sales personnel, 228 technical personnel, 64 financial personnel, and 210 administrative personnel [63]. - The educational background of employees showed that 307 held a bachelor's degree or higher, 430 had a college diploma, 489 had high school or vocational education, and 470 had education below high school [63]. - The company has implemented targeted employee training programs to enhance skills and improve overall team collaboration [65]. - The company has implemented a training plan to enhance employee skills and capabilities, aligning with its strategic goals [47]. Risk Management - The company faces risks related to environmental protection and safety production, which may impact operational goals [80]. - The company has not experienced any penalties or corrective actions during the reporting period, indicating stable operational compliance [150]. - The company has not reported any significant changes in project feasibility during the reporting period [89]. - The company has not reported any major contracts or high-risk entrusted financial management situations during the reporting period [177][175]. Investment and Capital Management - The company has invested a total of 1,687,461,483.26 yuan in fundraising projects as of December 31, 2022 [88]. - The company has not changed any fundraising projects during the reporting period [93]. - The company has not sold any significant assets during the reporting period [94]. - The company reported a total guarantee amount of 220,200,000 RMB during the reporting period, with an actual guarantee amount of 158,200,000 RMB for Harbin Shengtai Biological Pharmaceutical Co., Ltd. [173]. - The total approved guarantee amount at the end of the reporting period is 190,200 [188]. - Actual guarantee balance at the end of the reporting period is 163,000, representing 69.75% of the company's net assets [188]. - The total amount of guarantees exceeding 50% of net assets is 163,000 [188]. Social Responsibility - The company actively participated in social welfare and charity, promoting employment for over 200 individuals through partnerships with educational institutions [101]. - The company has adhered to the principle of "customer first," providing high-quality products and services while strengthening communication and cooperation with suppliers [125].

证券代码：000766 证券简称：通化金马 通化金马药业集团股份有限公司投资者关系活动记录表 编号：20180625 | --- | --- | |-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Group 1: Investor Relations Activities - The company participated in the 2021 Jilin Province online collective performance briefing on May 14, 2021 [1] - The event was held on the "Investor Relations Interactive Platform" provided by Shenzhen Panorama Network Co., Ltd. [1] Group 2: Key Questions and Answers - Question about whether the company's drugs will be included in the medical insurance directory this year; the company is monitoring the situation [1][2] - Inquiry regarding the company's plans for share repurchase; currently, there are no plans for share buyback [1][2] - Question about other new drugs in development besides the Amber Dihydroaminoacridine Tablets; the company has two invested drug research institutions [2] - Inquiry about the resolution of the company's debt issues related to the controlling shareholder's equity pledge dispute, which is currently in judicial proceedings [2] - Question regarding the timeline for the new drug launch; the Amber Dihydroaminoacridine Tablets have completed enrollment of 600 cases, with results expected by July or August 2021 [2]

Financial Performance - The company's revenue for Q3 2022 was ¥320,028,100.12, representing a 7.15% increase compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2022 was ¥4,934,969.58, a significant increase of 168.78% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥2,816,207.15, up 126.94% from the previous year[3]. - Basic earnings per share for Q3 2022 were ¥0.0051, an increase of 168.92% year-on-year[3]. - Total operating revenue for the current period is CNY 1,013,753,250.35, a decrease of 6.44% compared to CNY 1,083,496,299.71 in the previous period[12]. - Net profit for the current period is CNY 11,726,341.24, down from CNY 14,755,027.29, representing a decline of 20.56%[13]. - Earnings per share (EPS) for the current period is CNY 0.0129, compared to CNY 0.0163 in the previous period, a decrease of 20.87%[14]. - The total comprehensive income attributable to shareholders of the parent company is CNY 12,464,829.48, down from CNY 15,783,388.55, a decrease of 20.66%[14]. Cash Flow - The operating cash flow net amount for the year-to-date period reached ¥88,676,122.92, reflecting a 90.71% increase compared to the same period last year[3]. - The net cash flow from operating activities for the current period is ¥88,676,122.92, an increase of 90.5% compared to ¥46,498,512.34 in the previous period[16]. - Total cash inflow from operating activities is ¥1,074,408,967.19, down 7.2% from ¥1,157,570,001.91 in the previous period[15]. - Cash outflow from operating activities totals ¥985,732,844.27, a decrease of 11.3% compared to ¥1,111,071,489.57 in the previous period[16]. - The company reported a net cash flow from investing activities of -¥15,353,252.35, a decline from a positive cash flow of ¥10,437,192.56 in the previous period[16]. - Cash inflow from financing activities is ¥1,607,000,000.00, significantly higher than ¥27,399,900.00 in the previous period[16]. - Cash outflow from financing activities increased to ¥1,708,327,368.30 from ¥255,023,019.56 in the previous period[16]. - The ending balance of cash and cash equivalents is ¥174,697,669.66, down from ¥243,837,836.25 in the previous period[16]. - The company received ¥2,160.12 in tax refunds, compared to none in the previous period[15]. - The total cash outflow for investing activities is ¥20,478,485.27, slightly up from ¥20,284,082.29 in the previous period[16]. Assets and Liabilities - Total assets at the end of Q3 2022 were ¥4,572,028,207.89, a decrease of 1.48% from the end of the previous year[3]. - The company's total current assets as of September 30, 2022, amount to ¥1,117,099,235.59, a decrease from ¥1,151,684,009.21 at the beginning of the year[10]. - The total assets of the company are ¥4,572,028,207.89, down from ¥4,640,791,421.63[10]. - The total non-current assets are ¥3,454,928,972.30, down from ¥3,489,107,412.42[10]. - The total current liabilities amount to ¥562,108,879.70, significantly reduced from ¥2,027,548,716.60[10]. - Total liabilities amount to CNY 2,220,989,414.39, a decrease from CNY 2,301,478,969.37, reflecting a reduction of 3.52%[11]. - Long-term borrowings increased to ¥1,575,820,000.00 from ¥183,750,000.00[10]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 36,608[7]. - The largest shareholder, Yu Lanjun, holds 19.66% of shares, totaling 190,000,000 shares, with 150,000,000 shares pledged[7]. - The company's equity attributable to shareholders increased to ¥2,319,172,894.35, a rise of 0.54% compared to the end of the previous year[3]. - Total equity attributable to shareholders of the parent company is CNY 2,319,172,894.35, an increase from CNY 2,306,708,064.87, showing a growth of 0.54%[11]. Research and Development - Research and development expenses for the year-to-date period were ¥24,238,112.30, an increase of 45.64% compared to the same period last year[5]. - Research and development expenses increased to CNY 24,238,112.30 from CNY 16,642,133.39, marking a rise of 45.66%[12]. Other Financial Information - The company received government subsidies amounting to ¥2,457,710.56 in Q3 2022, contributing to its non-recurring gains[4]. - The company reported a significant decrease in investment income, with a loss of ¥3,746,157.64, down 138.32% year-on-year[5]. - Financial expenses for the current period are CNY 57,056,147.81, slightly down from CNY 59,576,109.93, a decrease of 4.23%[12]. - Deferred income decreased to CNY 73,669,209.18 from CNY 78,897,735.40, a decline of 6.67%[11]. - The company has not undergone an audit for the third quarter report[17].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥693,725,150.23, a decrease of 11.61% compared to ¥784,818,175.45 in the same period last year[11]. - The net profit attributable to shareholders was ¥7,529,859.90, down 67.20% from ¥22,958,542.68 year-on-year[11]. - The net profit after deducting non-recurring gains and losses was ¥3,722,972.58, a decline of 76.71% compared to ¥15,984,176.81 in the previous year[11]. - The basic earnings per share were ¥0.0078, down 67.23% from ¥0.0238 in the same period last year[11]. - The diluted earnings per share were also ¥0.0078, reflecting the same percentage decrease as the basic earnings per share[11]. - Operating profit was ¥18,530,551.00, down 58.10% year-on-year[22]. - Total profit amounted to ¥18,481,743.32, reflecting a decline of 56.82% compared to the previous year[22]. - The company reported a net loss of CNY 2,403,334,263.22 as of June 30, 2022, compared to a loss of CNY 2,410,864,123.12 at the beginning of the year[104]. - The company reported a net loss of ¥13,880,560.33 for the first half of 2022, compared to a net profit of ¥10,429,684.43 in the same period of 2021[111]. Cash Flow and Investments - The net cash flow from operating activities increased significantly by 496.25%, reaching ¥58,097,322.65, compared to ¥9,743,732.72 in the same period last year[11]. - The company reported a net cash outflow from investing activities of ¥9,430,665.56, a 160.69% decline year-on-year[30]. - The company reported a net cash outflow from investment activities of ¥6,292,860.94, a decrease from a net inflow of ¥6,874,058.29 in the previous year[115]. - Cash flow from financing activities resulted in a net outflow of ¥68,223,115.43, compared to a net outflow of ¥61,351,304.78 in the same period last year[115]. - The ending balance of cash and cash equivalents was ¥66,849,336.81, down from ¥183,523,839.97 at the end of the previous year[115]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,616,142,737.74, a slight decrease of 0.53% from ¥4,640,791,421.63 at the end of the previous year[11]. - The total liabilities as of June 30, 2022, were CNY 2,269,754,047.57, slightly down from CNY 2,301,478,969.37 at the beginning of the year[104]. - Cash and cash equivalents decreased to ¥278,913,905.28, representing 6.04% of total assets[35]. - Accounts receivable increased to ¥413,642,073.48, making up 8.96% of total assets[35]. - The company's total equity decreased to CNY 4,154,417,954.39 from CNY 4,168,298,514.72, a decline of 0.3%[106]. Research and Development - R&D investment increased to ¥21,355,042.90, a 50.88% rise compared to the previous year[30]. - Research and development expenses increased significantly to CNY 18,946,335.68, up from CNY 7,707,267.19, marking a rise of 146.5%[107]. - The company is advancing the Phase III clinical trial of its new drug, Succinic Acid Dihydrochloride Tablets, with pharmaceutical research completed[25]. - The company has acquired a company developing a new Alzheimer's treatment, enhancing its R&D capabilities in the pharmaceutical sector[26]. Market and Industry Position - The company operates in the pharmaceutical manufacturing industry, focusing on research, production, and sales of various medical products[18]. - The main products include compound probiotics, rheumatism pain relief capsules, and various traditional Chinese medicine formulations[18]. - The future outlook for the traditional Chinese medicine industry is optimistic, driven by increasing healthcare awareness and government support[18]. - The company focused on enhancing sales channels and expanding market presence, particularly in underdeveloped areas[24]. Corporate Governance and Shareholder Matters - The actual controller of Tonghua Jinma Pharmaceutical Group Co., Ltd. has changed to Mr. Yu Lanjun, with the announcement made on June 10, 2022[64]. - The company reported a significant change in control, with the major shareholder now being Mr. Yu Lanjun as of June 10, 2022[67]. - The company has committed to maintaining the independence of its operations, ensuring that key management personnel do not hold positions in other companies controlled by the major shareholder[68]. - The company has established measures to ensure compliance with market standards in related party transactions[66]. - The company has confirmed that there are no existing competitive businesses under the control of Mr. Zhang Yufu[66]. Environmental and Social Responsibility - The average COD concentration of wastewater in the first half of 2022 was 10.67 mg/L, with a total of 127,831 tons of wastewater treated[59]. - The company achieved a COD emission reduction of 112 tons and an ammonia nitrogen reduction of 0.092 tons in the first half of 2022[59]. - The company invested 8.2 million yuan to build a 1,000 t/a wastewater treatment plant, which has been operational since 2018[59]. - The company actively participated in poverty alleviation and rural revitalization efforts as part of its social responsibility initiatives[63]. Compliance and Legal Matters - There were no significant litigation or arbitration matters during the reporting period[72]. - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[70]. - The company has no bankruptcy reorganization matters during the reporting period[70]. Accounting and Financial Reporting - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that its financial statements accurately reflect its financial position and operating results[137]. - The company’s accounting policies and estimates are tailored to its operational characteristics, following relevant accounting standards[136]. - The company’s consolidated financial statements include all subsidiaries under its control, reflecting the overall financial status and performance of the group[145].

Financial Performance - The company's revenue for Q1 2022 was ¥357,550,409.09, a decrease of 6.64% compared to ¥382,987,117.99 in the same period last year[1] - Net profit attributable to shareholders increased by 42.19% to ¥5,788,129.66 from ¥4,070,763.78 year-on-year[1] - The net profit after deducting non-recurring gains and losses surged by 360.91% to ¥4,263,414.14 compared to ¥924,990.49 in the previous year[1] - Basic and diluted earnings per share rose by 42.86% to ¥0.0060 from ¥0.0042 year-on-year[1] - Total operating revenue for Q1 2022 was CNY 357,550,409.09, a decrease of 6.4% from CNY 382,987,117.99 in Q1 2021[13] - Net profit for Q1 2022 was CNY 5,583,342.14, an increase of 49.5% compared to CNY 3,731,956.70 in Q1 2021[14] Cash Flow - Operating cash flow for the period was ¥6,770,028.14, reflecting a significant increase of 357.11% from ¥1,481,060.68 in the same quarter last year[1] - Operating cash inflow for the current period was ¥306,207,804.95, a decrease of 15.3% from ¥361,364,592.59 in the previous period[16] - Operating cash outflow for the current period was ¥299,437,776.81, down 16.8% from ¥359,883,531.91 in the previous period[16] - Net cash flow from operating activities increased to ¥6,770,028.14, compared to ¥1,481,060.68 in the previous period[16] - Cash flow from investment activities resulted in a net outflow of ¥6,916,875.85, an improvement from a net outflow of ¥10,418,366.92 in the previous period[17] - Cash flow from financing activities showed a net outflow of ¥43,864,360.08, slightly better than the previous period's outflow of ¥44,971,072.19[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,634,838,733.13, a slight decrease of 0.13% from ¥4,640,791,421.63 at the end of the previous year[1] - The company's cash and cash equivalents decreased to approximately RMB 258.43 million from RMB 301.59 million, reflecting a decline of about 14.3%[10] - Accounts receivable increased to approximately RMB 426.97 million, up from RMB 350.61 million, indicating a growth of about 21.7%[10] - Inventory decreased to approximately RMB 367.26 million from RMB 384.58 million, a reduction of about 4.5%[11] - Total liabilities decreased slightly to CNY 2,289,942,938.73 from CNY 2,301,478,969.37 in the previous year[12] - The company’s total liabilities included short-term borrowings of RMB 40 million, remaining stable compared to the previous period[11] Research and Development - The company's R&D expenses increased by 165.57% to ¥8,393,049.09 from ¥3,160,401.87 in the same period last year, indicating a strong focus on innovation[3] - R&D expenses increased significantly to CNY 8,393,049.09, up 165.5% from CNY 3,160,401.87 in the same period last year[13] - The company plans to continue focusing on R&D and market expansion strategies to drive future growth[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 41,300, with no preferred shareholders[4] - The proportion of shares held by the largest shareholder, Yu Lanjun, increased to 19.66% after the judicial auction of shares held by Beijing Jinshang[9] - The company is facing legal disputes involving its major shareholder, which has resulted in a reduction of shareholding percentage[9] Other Financial Metrics - The weighted average return on net assets was 0.25%, up from 0.18% in the previous year[1] - The company reported a total of 1,149.82 million in current assets, slightly down from 1,151.68 million at the beginning of the year[11] - Long-term equity investments were valued at approximately RMB 55.11 million, a minor decrease from RMB 56.03 million[11] - The company reported a significant reduction in sales expenses to CNY 199,604,097.25, down 13.2% from CNY 230,032,417.37 in the previous year[13] Audit Status - The first quarter report was not audited[18]

Financial Performance - The company's operating revenue for 2021 was ¥1,515,482,473.31, an increase of 36.31% compared to ¥1,111,802,396.45 in 2020[12]. - The net profit attributable to shareholders for 2021 was ¥35,273,252.71, a 109.81% increase from a loss of ¥359,496,105.33 in 2020[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥20,304,105.76, up 104.82% from a loss of ¥421,277,176.76 in 2020[12]. - The net cash flow from operating activities for 2021 was ¥138,329,704.76, representing a 71.40% increase from ¥80,705,132.34 in 2020[12]. - The total assets at the end of 2021 were ¥4,640,791,421.63, a decrease of 6.76% from ¥4,977,076,111.43 at the end of 2020[12]. - The company reported a weighted average return on equity of 1.54% for 2021, compared to -14.62% in 2020[12]. - The company achieved a total revenue of ¥1,515,482,473.31, representing a year-on-year growth of 36.31%[25]. - The net profit attributable to shareholders reached ¥35,273,252.71, marking a significant increase of 109.81% compared to the previous year[24]. - The revenue from traditional Chinese medicine amounted to ¥610,540,935.78, which is 40.29% of total revenue and reflects a growth of 55.31% year-on-year[25]. - The revenue from chemical drugs was ¥900,175,655.09, accounting for 59.40% of total revenue, with a year-on-year increase of 26.24%[25]. Research and Development - The company has focused on talent development, emphasizing a younger and more professional management team to support future growth[24]. - The company has implemented comprehensive quality management practices to ensure compliance with GMP standards across all production processes[24]. - The company’s R&D expenses increased by 26.20% to 63,515,492.26 yuan in 2021[33]. - Research and development (R&D) investment amounted to ¥76,137,717.71, representing a 31.46% increase from ¥57,916,518.70 in the previous year[36]. - The number of R&D personnel decreased by 3.25% to 327, while the proportion of R&D personnel in the total workforce increased to 18.66% from 16.98%[36]. - The company is investing heavily in R&D, with a budget allocation of 10 million yuan for developing new technologies and products in the upcoming year[82]. - The company aims to enhance its R&D capabilities and product portfolio, focusing on the development of Amber Dihydroaminoacridine tablets and accelerating the progress of generic drug research[61]. - The company is conducting Phase III clinical trials for its key R&D project, aiming to develop a treatment for Alzheimer's disease[34]. Operational Strategy - The company operates in the pharmaceutical manufacturing industry, focusing on research, production, and sales of various medical products, including oncology, cardiovascular, and gastrointestinal drugs[20]. - The company has implemented a "production based on sales" model, aligning production plans with sales forecasts and inventory levels to enhance operational efficiency[21]. - The new sales system has led to a significant increase in main business revenue, reflecting the company's adaptation to changes in national drug policies and market trends[21]. - The company has established a comprehensive management mechanism across procurement, production, sales, quality control, and R&D, ensuring high decision-making efficiency[23]. - The management team is experienced and multidisciplinary, ensuring effective strategic planning and execution in a rapidly changing market environment[23]. - The company plans to optimize production quality management and improve supply chain integration to ensure the availability of all sales varieties[61]. - The company has strengthened its internal control systems and cost management to enhance operational efficiency and risk prevention[24]. Market Position and Growth - The company plans to focus on product layout and accelerate technological innovation to enhance market competitiveness in response to industry trends and policy changes[18]. - The company anticipates continued growth in the pharmaceutical market driven by population growth, aging demographics, and increased health awareness[60]. - The company is focused on becoming a comprehensive health manufacturing entity, integrating traditional Chinese medicine, biological drugs, and chemical drugs[60]. - The company is considering strategic acquisitions to enhance its product portfolio, with potential targets identified in the healthcare sector[82]. - A new product line is set to launch in Q2 2022, expected to contribute an additional 5 million yuan in revenue within the first year[82]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2023[116]. - The company provided a positive outlook for 2022, projecting a revenue growth of 25% based on new product launches and market expansion strategies[118]. Governance and Compliance - The company has established a robust internal control system to ensure compliance with financial regulations and effective governance[71]. - The company maintains independent operations and decision-making processes, ensuring no undue influence from major shareholders[67]. - The company has a complete and standardized operational system for research and development, production, and sales of pharmaceutical products, demonstrating its independent market operation capability[71]. - The company has a performance-based compensation policy linked to individual capabilities and performance management[96]. - The company has not engaged in significant related-party transactions with its controlling shareholder or other enterprises under its control[71]. - The company has established an independent personnel management department and a complete personnel management system, ensuring that senior management does not hold positions in the controlling shareholder's enterprises[70]. Environmental Responsibility - The company has committed to environmental protection as a key part of its sustainable development strategy, focusing on reducing energy consumption and enhancing resource efficiency[113]. - The company has successfully passed environmental assessments for its raw material workshop renovation project, ensuring compliance with environmental standards[111]. - The company reported a total COD discharge of 2.41 tons and ammonia nitrogen discharge of 0.026 tons in 2021[107]. - The company achieved a 100% compliance rate for wastewater treatment in 2021, processing a total of 127,831 tons of wastewater with an average COD concentration of 18.19 mg/L and ammonia nitrogen concentration of 0.207 mg/L[109]. - The company has implemented a solid waste management system, effectively handling hazardous waste and other solid waste, with all waste disposed of in compliance with regulations[110]. Shareholder Information - The company plans not to distribute cash dividends, nor issue bonus shares, or increase capital from reserves[2]. - The total number of shares outstanding is 966,494,707, with 26.85% being restricted shares and 73.15% being unrestricted shares[162]. - The largest shareholder, Beijing Jinshang Alliance Investment Management Co., Ltd., holds 23.91% of the shares, totaling 231,064,944 shares, with a decrease of 10,400 shares during the reporting period[165]. - The company has not issued any new securities during the reporting period[164]. - The company has a cash dividend policy in place, with no adjustments made during the reporting period, and plans to not distribute cash dividends or issue bonus shares[98].

Financial Performance - The company's revenue for Q3 2021 was ¥298,678,124.26, a decrease of 7.28% compared to the same period last year, while year-to-date revenue reached ¥1,083,496,299.71, an increase of 40.58%[2] - The net profit attributable to shareholders for Q3 2021 was -¥7,175,154.13, a significant decline of 91.55% year-on-year, but the year-to-date net profit was ¥15,783,388.55, up 109.97%[2] - Total operating revenue for the third quarter reached CNY 1,083,496,299.71, an increase of 40.5% compared to CNY 770,717,317.09 in the same period last year[12] - Net profit for the period was CNY 14,755,027.29, a significant recovery from a net loss of CNY 159,229,914.68 in the previous year[13] - The total comprehensive income attributable to the parent company was CNY 15,783,388.55, a decrease from CNY -158,387,008.16 in the previous period[14] Cash Flow - The net cash flow from operating activities for the year-to-date period increased by 263.75% to ¥46,498,512.34[2] - The net cash flow from operating activities was CNY 46,498,512.34, significantly up from CNY 12,783,239.05 in the previous period[16] - Cash inflows from operating activities totaled CNY 1,157,570,001.91, compared to CNY 994,104,604.00 in the previous period[16] - Cash outflows for operating activities amounted to CNY 1,111,071,489.57, an increase from CNY 981,321,364.95 in the previous period[16] - The net cash flow from investing activities was CNY 10,437,192.56, recovering from a negative CNY -460,170,565.36 in the previous period[16] - Cash inflows from financing activities were CNY 27,399,900.00, down from CNY 1,219,600,000.00 in the previous period[17] - The net cash flow from financing activities was CNY -227,623,119.56, compared to CNY 555,942,906.16 in the previous period[17] - The ending cash and cash equivalents balance was CNY 243,837,836.25, down from CNY 387,038,086.04 in the previous period[17] Assets and Liabilities - Total assets at the end of Q3 2021 were ¥4,727,702,660.23, reflecting a decrease of 5.01% from the end of the previous year[2] - The report indicated that the company reported a total asset value of CNY 4,727,702,660.23, down from CNY 4,977,076,111.43, a decrease of 5%[11] - Total liabilities decreased to CNY 2,407,623,359.33 from CNY 2,671,751,837.82, reflecting a reduction of 9.8%[11] - The company's long-term equity investments decreased slightly to ¥55.18 million from ¥57.41 million[9] - Fixed assets increased to ¥817.39 million from ¥720.71 million, indicating a growth of approximately 13.4%[9] Shareholder Information - The total number of common shareholders at the end of the reporting period was 40,449[6] - The largest shareholder, Beijing Jinshang Alliance Investment Management Co., Ltd., holds 23.91% of shares, totaling 231,064,944 shares[6] - The second-largest shareholder, Yu Lanjun, owns 19.66% of shares, amounting to 190,000,000 shares[6] - The company has a total of 150,000,000 shares involved in margin trading[6] - The shareholder structure indicates that several shareholders are involved in pledged or frozen shares, with the largest being 231,064,944 shares pledged by Beijing Jinshang Alliance[6] Operational Insights - Operating income increased by 40.58% year-on-year due to recovery in sales after the pandemic[4] - Research and development expenses decreased by 44.09% compared to the same period last year[4] - The company completed an asset swap involving the disposal of receivables valued at ¥105.99 million and the acquisition of 100% equity in a trading company, valued at ¥105.96 million[7] - The board approved a guarantee limit of ¥300 million for subsidiaries, with specific limits of ¥100 million for Chengdu Yongkang Pharmaceutical Co., Ltd. and ¥200 million for Harbin Saintai Biological Pharmaceutical Co., Ltd.[7] Challenges and Future Outlook - The company is facing legal challenges related to its controlling shareholder, which may impact its stock holdings and financial stability[7] - The report does not provide specific financial performance metrics or future guidance[6] - There is no mention of new product development or technological advancements in the current report[6] - The company has not disclosed any market expansion or acquisition strategies in this report[6] - Future outlook includes continued focus on market expansion and new product development, although specific figures were not provided in the report[12]

Financial Performance - The company's operating revenue for the reporting period was ¥784,818,175.45, representing a 74.95% increase compared to ¥448,598,085.55 in the same period last year[10]. - The net profit attributable to shareholders of the listed company was ¥22,958,542.68, a significant turnaround from a loss of ¥73,443,877.55, marking a 131.26% increase[10]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥15,984,176.81, compared to a loss of ¥95,452,067.31 in the previous year, reflecting a 116.75% improvement[10]. - The net cash flow from operating activities was ¥9,743,732.72, up 94.16% from ¥5,018,356.57 in the same period last year[10]. - The basic earnings per share increased to ¥0.0238 from a loss of ¥0.0760, representing a 131.32% improvement[10]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,850,122,880.17, a decrease of 2.55% from ¥4,977,076,111.43 at the end of the previous year[10]. - The net assets attributable to shareholders of the listed company were ¥2,294,393,354.84, showing a slight increase of 1.01% from ¥2,271,434,812.16 at the end of the previous year[10]. - Total liabilities included long-term borrowings of ¥1,788,300,000.00, which accounted for 36.87% of total liabilities[27]. - Total liabilities decreased to ¥2,522,511,300.90 from ¥2,671,751,837.82, a reduction of approximately 5.6%[90]. Revenue Breakdown - Revenue from traditional Chinese medicine was ¥316,610,734.60, accounting for 40.34% of total revenue, with a year-on-year growth of 111.76%[24]. - Chemical medicine revenue was ¥465,982,604.59, representing 59.37% of total revenue, with a year-on-year increase of 57.18%[24]. - The company reported a significant revenue increase of 136.31% in the North China region, totaling ¥148,023,290.41[25]. - The South Central region saw a revenue increase of 119.35%, amounting to ¥86,535,548.53[25]. Investment and R&D - The company's R&D investment decreased by 38.96% to ¥14,153,720.06 from ¥23,186,795.80 in the previous year, indicating a reduction in research spending[21]. - The company reported R&D expenses of ¥7,707,267.19 for the first half of 2021, down from ¥21,448,089.00 in the same period of 2020, indicating a decrease of approximately 64%[96]. - The company has a total of 42 invention patents and 71 utility model patents, emphasizing its commitment to developing and protecting its intellectual property[20]. Operational Efficiency - The company reported a net increase in cash flow from operating activities, indicating improved operational efficiency[10]. - The marketing strategy has been restructured to enhance market share and sales performance, resulting in significant revenue growth[17]. - The company has implemented a "production based on sales" model, ensuring production aligns with market demand and inventory levels[15]. Corporate Governance and Compliance - The company has strengthened its internal control systems and governance, focusing on legal compliance and risk management to enhance operational efficiency[18]. - The company has established a comprehensive governance structure and internal control system to protect shareholder and creditor rights, ensuring fair access to legal rights[50]. - The company has not reported any major litigation or arbitration matters during the reporting period[54]. Environmental and Social Responsibility - The company actively participates in social responsibility initiatives, donating 500,000 yuan for pandemic prevention efforts and engaging in poverty alleviation programs[51]. - The company has implemented measures to comply with increasing environmental protection standards, including upgrades to its boiler emissions systems[45]. - The company has effectively managed solid waste, including hazardous waste, ensuring proper disposal through qualified treatment units[48]. Shareholder Information - The company has maintained a 47.18% investor participation rate in its annual shareholder meeting held on June 11, 2021[40]. - The total number of ordinary shareholders at the end of the reporting period was 41,201, with no significant changes reported[76]. - The major shareholder, Beijing Jinshang Alliance, holds 241,464,944 shares, which is subject to pledges and freezes[78]. Financial Instruments and Accounting Policies - The company adheres to the Chinese Accounting Standards, ensuring the accuracy and completeness of its financial reporting[125]. - The company recognizes deferred tax assets related to deductible temporary differences only if they meet the recognition criteria at the acquisition date[132]. - Financial instruments are classified at initial recognition based on the company's management business model and cash flow characteristics[142]. Future Outlook and Strategy - The company is focused on future growth strategies, including potential market expansion and new product development[2]. - The company is adapting to changes in national pharmaceutical policies to better position itself in the market[16]. - The company aims to enhance its asset structure and business efficiency through strategic investments and asset management[35].

通化金马药业集团股份有限公司 2021 年第一季度报告全文 通化金马药业集团股份有限公司 2021 年第一季度报告 2021 年 04 月 1 通化金马药业集团股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人战红君、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证季度报告中财务报表的真实、准确、完整。 2 通化金马药业集团股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | | | | | | ...